Emibetuzumab LY2875358|cas:1365287-97-3|西域试剂

Emibetuzumab LY2875358,95.00%

产品编号：Bellancom-P99192| CAS NO：1365287-97-3

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P99192	￥1800.00	杭州北京（现货）
Bellancom-P99192	￥5400.00	杭州北京（现货）
Bellancom-P99192	￥8600.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Emibetuzumab LY2875358

产品介绍

Emibetuzumab (LY2875358) 是一种人源化二价 MET 抗体 (IgG4 型)。Emibetuzumab 具有较高的中和与内化活性，能有效抑制 HGF 依赖性和非依赖性 MET 通路的激活和肿瘤生长。Emibetuzumab 可用于癌症的研究。

生物活性

Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer.

体外研究

Emibetuzumab (LY2875358) (100 nmol/L; 6 days) inhibits HGF-stimulated proliferation of H596.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line:	H596 cells (HGF-stimulated)
Concentration:	100 nmol/L
Incubation Time:	6 days
Result:	Suppressed cell proliferation.

体内研究
(In Vivo)

Emibetuzumab (LY2875358) (10 mg/kg; i.v.; once a week for 5 weeks) inhibits in vivo growth of glioblastoma U87MG xenograft tumors in mice.
Emibetuzumab (10 or 20 mg/kg; i.v.; single) downregulates levels of MET and pMET in the tumors of mice.
Emibetuzumab (10 mg/kg; i.v.; once a week for 3, 5 or 6 weeks) exhibits antitumor effects on MET-amplified xenograft mouse tumor models.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Athymic nude mice (U87MG tumor xenograft model).
Dosage:	10 mg/kg
Administration:	Intravenous injection, once a week for 5 weeks.
Result:	Demonstrated a significant inhibition of tumor growth.

Animal Model:	Athymic nude mice (MKN45 xenograft tumor model).
Dosage:	10 or 20 mg/kg
Administration:	Intravenous injection, single.
Result:	Reduced MET and pMET in the tumors by approximately 50% at both the 10 and 20 mg/kg doses by 72 hours post dose, and the reductions persisted to 14 days.

Animal Model:	Athymic nude mice (MET-amplified xenograft mouse tumor models).
Dosage:	10 mg/kg
Administration:	Intravenous injection, once a week for 3, 5 or 6 weeks.
Result:	Resulted in a marked reduction in tumor growth in the MKN45/SNU-5/EBC-1 gastric xenograft tumors.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Athymic nude mice (U87MG tumor xenograft model).
Dosage:	10 mg/kg
Administration:	Intravenous injection, once a week for 5 weeks.
Result:	Demonstrated a significant inhibition of tumor growth.

Animal Model:	Athymic nude mice (MKN45 xenograft tumor model).
Dosage:	10 or 20 mg/kg
Administration:	Intravenous injection, single.
Result:	Reduced MET and pMET in the tumors by approximately 50% at both the 10 and 20 mg/kg doses by 72 hours post dose, and the reductions persisted to 14 days.

Animal Model:	Athymic nude mice (MET-amplified xenograft mouse tumor models).
Dosage:	10 mg/kg
Administration:	Intravenous injection, once a week for 3, 5 or 6 weeks.
Result:	Resulted in a marked reduction in tumor growth in the MKN45/SNU-5/EBC-1 gastric xenograft tumors.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Athymic nude mice (U87MG tumor xenograft model).
Dosage:	10 mg/kg
Administration:	Intravenous injection, once a week for 5 weeks.
Result:	Demonstrated a significant inhibition of tumor growth.

Animal Model:	Athymic nude mice (MKN45 xenograft tumor model).
Dosage:	10 or 20 mg/kg
Administration:	Intravenous injection, single.
Result:	Reduced MET and pMET in the tumors by approximately 50% at both the 10 and 20 mg/kg doses by 72 hours post dose, and the reductions persisted to 14 days.

Animal Model:	Athymic nude mice (MET-amplified xenograft mouse tumor models).
Dosage:	10 mg/kg
Administration:	Intravenous injection, once a week for 3, 5 or 6 weeks.
Result:	Resulted in a marked reduction in tumor growth in the MKN45/SNU-5/EBC-1 gastric xenograft tumors.